Who Paid My Doc
Caroline Eggerding
Neurodevelopmental Disabilities Camden, NJ Medical Doctor
NPI 1285645689 CMS profile 240076
3 Cooper Plz Rm 200, Camden, NJ 08103
General payments
$73,484
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$5,354
Through program year 2024, Caroline Eggerding of Camden, NJ is reported in the CMS Open Payments database as having received $73,484 across 129 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $5,354 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 96th percentile of Neurodevelopmental Disabilities profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $2,277 | 7 | |
| 2023 | General | $31,078 | 57 | |
| 2022 | General | $20,047 | 26 | |
| 2021 | General | $7,625 | 11 | |
| 2020 | General | $4,833 | 5 | |
| 2019 | General | $7,623 | 23 |
Beside peers
- Caroline Eggerding
- Neurodevelopmental Disabilities median
- Middle half of Neurodevelopmental Disabilities
- National median
In program year 2025, general payments to Caroline Eggerding were reported at $0. Among 64 Neurodevelopmental Disabilities profiles paid that year, the median was $136 and the middle half received between $67 and $819.
Show as a table
| Year | Caroline Eggerding | Neurodevelopmental Disabilities median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $7,623 | $138 | $34–$757 | $163 |
| 2020 | $4,833 | $63 | $23–$471 | $114 |
| 2021 | $7,625 | $158 | $43–$1,017 | $132 |
| 2022 | $20,047 | $225 | $76–$1,106 | $149 |
| 2023 | $31,078 | $228 | $73–$994 | $160 |
| 2024 | $2,277 | $167 | $57–$1,310 | $164 |
| 2025 | $0 | $136 | $67–$819 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
129 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neurodevelopmental Disabilities in New Jersey
Thomas Rugino
Neurodevelopmental Disabilities · Toms River, NJ
Cynthia Cookson
Neurodevelopmental Disabilities · Paterson, NJ
Saidi Clemente
Neurodevelopmental Disabilities · Morristown, NJ
Fatema Jaffery
Neurodevelopmental Disabilities · Newark, NJ
Pahirathi Haran
Neurodevelopmental Disabilities · Denville, NJ
Vinod Goyal
Neurodevelopmental Disabilities · Newark, NJ
Related records
Neurodevelopmental Disabilities in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Neurodevelopmental Disabilities
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.